Why don't we challenge in developing innovative new drugs for patients suffering from acute diseases by integrating your strength in research with ours?

Pharmaceuticals Research Center
Laboratory for Pharmacology


Creating for Tomorrow

“ Critical Care Medicine ”


Pharmaceuticals Research Center

Shunsuke Tawara, PhD

Senior Principal Scientist
Pharmaceuticals Research Center

Asahi Kasei Pharma has contributed to the advancement of treatment for acute diseases through the development of medicines, including the anticoagulant Recomodulin® and the protein kinase inhibitor Eril®. We aim to develop novel drugs for different types of acute diseases using the knowledge we obtained during the research and development of these products.

The clinical conditions of acute diseases are complex. In addition, the progression rates of these conditions are high. Therefore, their pathophysiology can only be elucidated by scientists with highly specialized knowledge and skills. As a result, these scientists alone are capable of selecting clinically useful drug-target molecules for treating acute diseases. Drug discovery research requires interdisciplinary expertise with deep understanding of not onlypharmacology of drug efficacy, but also other scientific disciplines such as pharmacokinetics, toxicology, and chemical and biological synthesis. Thus, we are confident that research alliances involving partnerships between you (experts in the pathophysiology of acute diseases) and our company (professionals in drug discovery research) will result in the development of innovative new drugs that can improve quality of life of patients with acute diseases. We are eager to support developing your drug seeds by working with you. We look forward to receiving your proposals.

Recruitment theme 

Drug Candidates

3.1 New drug candidates for treating sepsis by activating immune responses
  • Proposals should ideally include in vivo data obtained from sepsis or infection models. (Laboratory animals injected with LPS are not considered sepsis models.)
3.2 New drug candidates for acute lung injury (ALI) or acute respiratory distress syndrome (ARDS)


Click “Apply” to proceed to the application form.